Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the ...

Needham reiterated a Hold rating for ResMed (NYSE:RMD), highlighting the company's second quarter fiscal year 2025 performance. ResMed reported revenue and earnings per share (EPS) that surpassed ...

Piper Sandler analyst Adam Maeder maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $260.00. The ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m ...

Shares of ResMed Inc. RMD rose 1.67% to $254.70 Monday, on what proved to be an all-around mixed trading session for the ...

ResMed (NYSE:RMD – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal second-quarter earnings of $344.6 million. On a per-share basis, the San Diego-based company said it had net income of ...

Shares of ResMed Inc. RMD advanced 1.89% to $257.65 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.53% to 6,071.17 and the ...